Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. develops novel product candidates for brain health disorders as a late-stage clinical biopharmaceutical company trading under MNMD. Its updates focus on a pipeline targeting neurotransmitter pathways, including MM120 Orally Disintegrating Tablet for generalized anxiety disorder and major depressive disorder and MM402 for autism spectrum disorder.
Recurring news includes clinical-program progress, quarterly financial results and business updates, underwritten public offerings, Nasdaq inducement option grants for new employees, and presentations at healthcare and investor conferences.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Dr. Sarah Y. Vinson as a director and member of the audit committee, effective immediately. Dr. Vinson is a triple board-certified psychiatrist with significant experience in child and adolescent psychiatry, and she aims to drive innovation in mental health treatments. Her appointment is part of a strategy to enhance board independence and expertise. Dr. Vinson will be nominated for election at the upcoming shareholder meeting on May 27, 2021. This appointment highlights MindMed's commitment to expanding its leadership in the psychedelic medicine sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) reported financial results for Q1 2021, with total assets of $201 million and a cash balance of $160 million. The company incurred a net loss of $14 million for the quarter, with a cash burn of $10 million. Key business developments include the acquisition of HealthMode, clinical trials for MDMA and LSD, and significant financing efforts totaling $73 million USD and $15.4 million USD. Management will discuss these results in an earnings call on May 17, 2021.
MindMed (NASDAQ: MNMD) has appointed Peter Mack, PhD, as Vice President of Pharmaceutical Development. He will oversee product development across MindMed's portfolio, including LSD and ibogaine derivative 18-MC. Previously, Peter held a senior role at AstraZeneca, contributing to inhalation therapies for respiratory diseases. His dual PhD from Harvard and MIT positions him to strengthen MindMed's development pipeline, focused on psychedelic-inspired medicines for addiction and mental health disorders. CEO J.R. Rahn expressed excitement over Mack's addition to the team.
On May 5, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced the launch of Project Angie to advance psychedelics, particularly LSD, for treating pain conditions. The company will initiate a Phase 2a Proof of Concept study, submitting a pre-IND briefing to the FDA in the latter half of 2021. With the global analgesics market projected to grow by over $31 billion by 2030, MindMed seeks to innovate within the pain treatment sector. Preliminary studies indicate psychedelics may offer a novel treatment mechanism for pain relief.
MindMed (Nasdaq: MNMD) has officially commenced trading on The Nasdaq Capital Market as of April 27, 2021. The company's shares previously traded on the OTCQB under the symbol MMEDF and will now be traded under the symbol MNMD. MindMed will also retain its listing on the Neo Exchange under the symbol MMED. The announcement includes a live bell ringing ceremony, highlighting the significance of this transition for the company, which focuses on developing psychedelic-inspired therapies for addiction and mental health.